Table 2.
TEAEs of all grades (in 25% patients or more overall) and grade 3 or higher severity (in 10% patients or more overall)
| TEAE | All grades, monotherapy OLU (n = 6), n (%) | All grades, combination OLU + AZA (n = 16), n (%) | Grade ≥3, monotherapy OLU (n = 6), n (%) | Grade ≥3, combination OLU + AZA (n = 16), n (%) |
|---|---|---|---|---|
| Patients with any TEAE | 6 (100) | 16 (100) | 6 (100) | 15 (94) |
| Fatigue | 4 (67) | 10 (63) | 1 (17) | 2 (13) |
| Nausea | 4 (67) | 9 (56) | 0 | 1 (6) |
| Constipation | 1 (17) | 9 (56) | 0 | 0 |
| Arthralgia | 4 (67) | 5 (31) | 1 (17) | 0 |
| Platelet count decreased | 2 (33) | 7 (44) | 2 (33) | 4 (25) |
| Vomiting | 2 (33) | 7 (44) | 0 | 0 |
| Neutrophil count decreased | 2 (33) | 6 (38) | 2 (33) | 6 (38) |
| Cough | 1 (17) | 6 (38) | 0 | 0 |
| Diarrhea | 1 (17) | 6 (38) | 0 | 1 (6) |
| Dizziness | 1 (17) | 6 (38) | 0 | 0 |
| Dyspnea | 2 (33) | 5 (31) | 0 | 1 (6) |
| Febrile neutropenia | 1 (17) | 5 (31) | 1 (17) | 5 (31) |
| Headache | 2 (33) | 4 (25) | 0 | 0 |
OLU, olutasidenib.